H90.A32 Insurance Policy Changes

ICD-10 H90.A32 is officially defined as "Mixed conductive and sensorineural hearing loss, unilateral, left ear with restricted hearing on the contralateral side." code H90.A32 is referenced in 3 tracked payer policy changes from Excellus BlueCross BlueShield and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code H90.A32 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Mar 19, 2026Medium impact
Cochlear Implants and Auditory Brainstem Implants 7.01.26
Excellus BlueCross BlueShield medical policy 7.01.26 covers cochlear implants and auditory brainstem implants and states when each is considered medically appropriate. Unilateral and bilateral cochlear implants are considered appropriate for bilateral severe-to-profound sensorineural hearing loss when all listed criteria are met, including a pure-tone average above 70 dB HL at 500, 1000 and 2000 Hz and limited or no benefit from appropriately fit hearing aids. The policy also covers unilateral implants for single-sided deafness or asymmetric hearing loss, hybrid cochlear implants, auditory brainstem implants for neurofibromatosis type 2, and repair and replacement of devices. The current effective date is March 19, 2026, and the April 22, 2026 edit added reference resources.
Aetna · Identified Oct 4, 2026Medium impact
Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation (CPB 0599, reviewed 2026-09-18)
Autologous skeletal myoblast transplantation, intra-coronary and intra-myocardial autologous bone marrow cell transplantation, and intra-arterial or intra-muscular autologous mononuclear bone marrow cell transplantation are considered experimental, investigational, or unproven because effectiveness has not been established. Autologous or allogeneic bone marrow-derived mesenchymal stem cell transplantation is likewise considered experimental, investigational, or unproven for conditions including acute myocardial infarction, diabetes, multiple sclerosis, knee osteoarthritis, spinal cord injury, rheumatoid arthritis, Crohn's disease, and peripheral nerve repair. CPT codes 0263T, 0264T, 0265T, 38240, and 38241 and HCPCS code C9782 are listed as not covered for the listed indications, and the ICD-10 codes for those indications are listed as not covered for these services.
Aetna · Identified Aug 17, 2026Medium impact
Meniere's Disease and Related Disorders: Surgery (CPB 0514, reviewed 2026-07-02)
Aetna considers these surgical interventions medically necessary for chronic refractory Meniere's disease: endolymphatic mastoid shunt, endolymphatic sac decompression or drainage, lateral semi-circular canal plugging, perilymphatic fistula patching, sacculotomy, tympanostomy tube insertion, vestibular nerve decompression, vestibular neurectomy or neurotomy, intra-tympanic corticosteroid injections or perfusions, cochleosacculotomy, intra-tympanic gentamicin, labyrinthectomy, translabyrinthine vestibular neurectomy and vestibulocochlear neurectomy. The policy also covers middle fossa craniotomy and trans-mastoid canal plugging for superior semicircular canal dehiscence when audiometry and computed tomography confirm the diagnosis, and intra-tympanic or trans-tympanic dexamethasone injection for sudden sensorineural hearing loss in members who failed conservative treatment including oral steroids or who have a medical condition that prohibits oral steroids. Aetna considers tenotomy of the stapedius and tensor tympani muscles, triple semi-circular canal plugging, positive pressure therapy for improving outcomes of endolymphatic sac surgery, cochleostomy with neurovascular transplant, intra-tympanic dexamethasone thermo-sensitive gel, and simultaneous labyrinthectomy with cochlear implantation for bilateral Meniere's disease experimental, investigational or unproven because their effectiveness has not been established.

Watch H90.A32

Get one email when a payer policy names H90.A32, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code H90.A32?

There are 3 tracked policy changes affecting code H90.A32, including updates from Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code H90.A32?

Payers that have issued tracked updates for code H90.A32 include: Excellus BlueCross BlueShield, Aetna.

How do I get notified when code H90.A32 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code H90.A32. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code H90.A32?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Cochlear Implants and Auditory Brainstem Implants 7.01.26

Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation (CPB 0599, reviewed 2026-09-18)

Meniere's Disease and Related Disorders: Surgery (CPB 0514, reviewed 2026-07-02)

What insurance policy changes affect code H90.A32?

Which payers have updated policy for code H90.A32?

How do I get notified when code H90.A32 policy changes?

Why do payers change policies for code H90.A32?